Video

Dr. Kearns on the Role of Surgery in High-Risk Prostate Cancer

James Kearns, MD, assistant professor of urology, Levine Cancer Institute, discusses the role of surgery in patients with high-risk prostate cancer.

James Kearns, MD, assistant professor of urology, Levine Cancer Institute, discusses the role of surgery in patients with high-risk prostate cancer.

Physicians have to decide whether surgery is the right option for patients on an individualized basis, Kearns says. It is an important conversation to have with patients, though some patients are inclined to opt for surgery, explains Kearns. An important factor is the patient’s risk tolerance. Because this is a high-risk population, it is expected that these patients will need further therapy down the line, whether it be radiation or hormone therapy. Physicians want to make sure that if patients undergo surgery, there is a good chance it will delay or eliminate the need for that future treatment. If later treatment is unavoidable, Kearns notes it is probably better to avoid the morbidity of surgery.

On the other hand, if a patient is skeptical about the procedure, it is important for the physician to outline the risks and benefits of surgery. However, Kearns adds that most patients seem to be willing to undergo the procedure.

Related Videos
Alan Tan, MD, genitourinary oncology and melanoma specialist, Vanderbilt-Ingram Cancer Center; associate professor, medicine, Division of Hematology Oncology, Vanderbilt University Medical Center
Zosia Piotrowska, MD, MHS, instructor, Harvard Medical School; medical oncologist, Massachusetts General Hospital
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD